

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 17:25:32 ON 28 JAN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 17:25:47 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 JAN 2008 HIGHEST RN 1000849-38-6
DICTIONARY FILE UPDATES: 27 JAN 2008 HIGHEST RN 1000849-38-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>


Uploading C:\Documents and Settings\jcho2\My Documents\10588478-a.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 Ak,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 17:26:07 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS

22 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 2671 TO 4249

PROJECTED ANSWERS: 159 TO 721

L2 22 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 17:26:26 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 3389 TO ITERATE

100.0% PROCESSED 3389 ITERATIONS

564 ANSWERS

SEARCH TIME: 00.00.01

L3 564 SEA SSS FUL L1


=> d scan

L3 564 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN


IN 1,4-Benzenedicarboxamide, N-[2-[bis[2-[[[1,2-dihydro-1-methyl-2-oxo-3-(phenylmethoxy)-4-pyridinyl]carbonyl]amino]ethyl]amino]ethyl]-N'-(4-oxo-7,10,13,16,19,22,25,28,31,34,37,40-dodecaoxa-3-azahentetracont-1-yl)-2,3-bis(phenylmethoxy)-(9CI)



MF C84 H112 N8 O23

PAGE 1-A



PAGE 1-B





PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=>

Uploading C:\Documents and Settings\jcho2\My Documents\10588478-b.str

L4 STRUCTURE UPLOADED

=> d 12

L2 ANSWER 1 OF 22 REGISTRY COPYRIGHT 2008 ACS on STN


RN 919772-33-1 REGISTRY

ED Entered STN: 07 Feb 2007

CN L-Alanine, N-[4-[[(2-aminoethyl) amino] carbonyl]-3-methoxybenzoyl]- (CA

INDEX NAME)
 FS STEREOSEARCH
 MF C14 H19 N3 O5
 SR CA
 LC STN Files: CA, CAPLUS, USPATFULL


Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
 1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> d 14
 L4 HAS NO ANSWERS
 L4 STR



G1 Ak,Cy

Structure attributes must be viewed using STN Express query preparation.

=> s 14 sss sam
 SAMPLE SEARCH INITIATED 17:31:42 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 173 TO ITERATE

100.0% PROCESSED 173 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 2671 TO 4249
PROJECTED ANSWERS: 0 TO 0

L5 0 SEA SSS SAM L4

=> s l4 sss full
FULL SEARCH INITIATED 17:31:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3389 TO ITERATE


100.0% PROCESSED 3389 ITERATIONS 27 ANSWERS
SEARCH TIME: 00.00.01

L6 27 SEA SSS FUL L4

=> d scan

L6 27 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
IN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-,
methyl ester
MF C27 H36 N2 O5

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> file caplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
362.86	363.07

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 17:32:05 ON 28 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 28 Jan 2008 VOL 148 ISS 5
FILE LAST UPDATED: 27 Jan 2008 (20080127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s l6

L7 4 L6


=> d l7 1-4 bib abs hitstr

L7 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:961964 CAPLUS
DN 143:248664
TI Preparation of terephthalamide peptidomimetic compounds for therapeutic use
IN Hamilton, Andrew D.; Yin, Hang
PA Yale University, USA
SO PCT Int. Appl., 48 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005079541	A2	20050901	WO 2005-US5557	20050222
	WO 2005079541	A3	20051103		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2005215051	A1	20050901	AU 2005-215051	20050222
	CA 2556447	A1	20050901	CA 2005-2556447	20050222
	EP 1723100	A2	20061122	EP 2005-713917	20050222
	R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU			
	US 2007123592	A1	20070531	US 2006-588478	20061002
PRAI	US 2004-546111P	P	20040219		
	WO 2005-US5557	W	20050222		
OS	CASREACT 143:248664; MARPAT 143:248664				
GI					



I



II

AB The invention relates to compds. and pharmaceutical compns. based on terephthalamide which are proteomimetic and methods for inhibiting the interaction of an α -helical protein with another protein or binding site and for treating diseases or conditions which are modulated through these interactions. Compds. I [X is H, halo, R, OR, SR or an amino group, where R is H, (un)substituted alkyl, acyl, aryl, heteroaryl, alkylenearyl or alkyleneheteroaryl; X₂, X₃, X₄ are independently H, halo, OH, Rc, ORc, where Rc is (un)substituted alkyl, acyl, aryl or alkylenearyl; R₄ is H, (un)substituted alkyl, alkenyl or alkylene amine; R', R_{1a}, R_{1b} are any group given for R₄ or (CH₂)₀₋₂CHR₂CO₂H or an alkyl ester, where R₂ is independently H or (un)substituted hydrocarbon, alkoxy, ester, alkanol, alkanolic acid, amine, etc.; or N-R' or NR_{1a}R_{1b} form an amino acid residue] are claimed. Thus, peptidomimetic compound II, prepared via coupling reaction of L-leucine Me ester hydrochloride, showed inhibitory constant K_i = 0.781 \pm 0.070 μ M in a fluorescence polarization assay (binding affinity for Bcl-XL).

IT 681466-00-2P


RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(conformation; preparation of terephthalamide peptidomimetic compds. for therapeutic use)

RN 681466-00-2 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 681465-54-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of terephthalamide peptidomimetic compds. for therapeutic use)

RN 681465-54-3 CAPLUS


CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 681465-56-5P 681465-60-1P 681465-62-3P
 681465-64-5P 681465-66-7P 681465-68-9P
 681465-70-3P 681465-74-7P 852065-21-5P
 852065-22-6P 852065-23-7P 852065-25-9P
 852065-26-0P 852065-27-1P 852065-28-2P
 852065-29-3P 852065-30-6P 852065-31-7P
 852065-32-8P 852065-33-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation of terephthalamide peptidomimetic compds. for therapeutic use)
 RN 681465-56-5 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-
 methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-60-1 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-62-3 CAPLUS
 CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-,
 methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-64-5 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-
(CA INDEX NAME)


Absolute stereochemistry.



RN 681465-66-7 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-naphthalenyloxy)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-68-9 CAPLUS

CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-70-3 CAPLUS

CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-74-7 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-21-5 CAPLUS


CN L-Phenylalanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-22-6 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-
 (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-23-7 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 852065-25-9 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(4-nitrophenoxy)benzoyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 852065-26-0 CAPLUS
 CN L-Alanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-,
 methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-27-1 CAPLUS

CN L-Leucine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-28-2 CAPLUS

CN L-Phenylalanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-29-3 CAPLUS

CN L-Alanine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-30-6 CAPLUS

CN L-Leucine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-31-7 CAPLUS

CN L-Alanine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-32-8 CAPLUS

CN L-Leucine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).




RN 852065-33-9 CAPLUS

CN L-Valine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



L7 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2005:267006 CAPLUS
 DN 142:482288
 TI Terephthalamide Derivatives as Mimetics of Helical Peptides: Disruption of the Bcl-xL/Bak Interaction
 AU Yin, Hang; Lee, Gui-in; Sedey, Kristine A.; Rodriguez, Johanna M.; Wang, Hong-Gang; Sebti, Said M.; Hamilton, Andrew D.
 CS Department of Chemistry, Yale University, New Haven, CT, 06520-8107, USA
 SO Journal of the American Chemical Society (2005), 127(15), 5463-5468
 CODEN: JACSAT; ISSN: 0002-7863
 PB American Chemical Society
 DT Journal
 LA English
 OS CASREACT 142:482288
 GI




AB A series of Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, was designed to mimic the α -helical region of the Bak peptide. These mols. showed favorable in-vitro activities in disrupting the Bcl-xL/Bak BH3 domain complex (terephthalamides I and II, $K_i = 0.78 \pm 0.07$ and $1.85 \pm 0.32 \mu\text{M}$, resp.). Extensive structure-affinity studies demonstrated a correlation between the ability of terephthalamide derivs. to disrupt Bcl-xL/Bak complex formation and the size of variable side chains on these mols. Treatment of human HEK293 cells with the terephthalamide derivative 26 resulted in disruption of the Bcl-xL/Bax interaction in whole cells with an IC_{50} of $35.0 \mu\text{M}$. Computational docking simulations and NMR expts. suggested that the binding cleft for the BH3 domain of the Bak peptide on the surface of Bcl-xL is the target area for these synthetic inhibitors.

IT 681465-54-3P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of terephthalamide derivs. as helical peptidomimetics and their evaluation as antagonists of Bcl-x/Bak protein interaction)


RN 681465-54-3 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 681465-56-5P 681465-58-7P 681465-60-1P
 681465-62-3P 681465-64-5P 681465-68-9P
 681465-70-3P 681465-74-7P 852065-21-5P
 852065-22-6P 852065-23-7P 852065-24-8P
 852065-25-9P 852065-26-0P 852065-27-1P
 852065-28-2P 852065-29-3P 852065-30-6P
 852065-31-7P 852065-32-8P 852065-33-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
 (Biological study); PREP (Preparation)
 (preparation of terephthalamide derivs. as helical peptidomimetics and their
 evaluation as antagonists of Bcl-x/Bak protein interaction)
 RN 681465-56-5 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-
 methylethoxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-58-7 CAPLUS
 CN L-Leucine, N-[4-[[[(1S)-1-carboxyethyl](2-methylpropyl)amino]carbonyl]-2-
 (1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 681465-60-1 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-,
 methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 681465-62-3 CAPLUS

CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-64-5 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-, (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-68-9 CAPLUS

CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-70-3 CAPLUS

CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-74-7 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-21-5 CAPLUS

CN L-Phenylalanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-22-6 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-23-7 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-24-8 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(2-naphthalenyloxy)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-25-9 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(4-nitrophenoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-26-0 CAPLUS

CN L-Alanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-27-1 CAPLUS

CN L-Leucine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 852065-28-2 CAPLUS


CN L-Phenylalanine, N-[4-[(dimethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 852065-29-3 CAPLUS
 CN L-Alanine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).




RN 852065-30-6 CAPLUS
 CN L-Leucine, N-[4-[(diethylamino)carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 852065-31-7 CAPLUS
 CN L-Alanine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-32-8 CAPLUS

CN L-Leucine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 852065-33-9 CAPLUS

CN L-Valine, N-[4-[[bis(2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2004:189140 CAPLUS
DN 140:350050
TI Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein
AU Yin, Hang; Hamilton, Andrew D.
CS Department of Chemistry, Yale University, New Haven, CT, 06511, USA
SO Bioorganic & Medicinal Chemistry Letters (2004), 14(6), 1375-1379
CODEN: BMCLE8; ISSN: 0960-894X
PB Elsevier Science B.V.
DT Journal
LA English
OS CASREACT 140:350050
AB A group of novel Bcl-xL/Bak antagonists, based on a terephthalamide scaffold, were designed to mimic the α -helical region of the Bak peptide. Good in vitro inhibition potencies in disrupting the Bak/Bcl-xL complex have been observed (terephthalamide 4, $K_i=0.78\pm0.07$ μ M).
IT 681465-54-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)
RN 681465-54-3 CAPLUS
CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 681465-56-5P 681465-58-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)

RN 681465-56-5 CAPLUS

CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-58-7 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-1-carboxyethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 681465-60-1 681465-62-3 681465-64-5
681465-66-7 681465-68-9 681465-70-3
681465-72-5 681465-74-7

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)

RN 681465-60-1 CAPLUS


CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 681465-62-3 CAPLUS
 CN D-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-methoxybenzoyl]-,
 methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-64-5 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-phenoxybenzoyl]-,
 (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-66-7 CAPLUS
 CN L-Leucine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-
 naphthalenyloxy)benzoyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-68-9 CAPLUS
 CN L-Alanine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 681465-70-3 CAPLUS
 CN L-Valine, N-[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 681465-72-5 CAPLUS
 CN Benzeneacetic acid, α -[[4-[[bis(1-methylethyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]amino]-, methyl ester, (α S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 681465-74-7 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-1-carboxy-2-methylpropyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 681466-00-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(terephthalamide derivs. as novel Bcl-xL/Bak antagonists)

RN 681466-00-2 CAPLUS

CN L-Leucine, N-[4-[[[(1S)-2-methoxy-1-methyl-2-oxoethyl](2-methylpropyl)amino]carbonyl]-2-(1-methylethoxy)benzoyl]-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RE.CNT 15 THERE ARE 15 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:394328 CAPLUS

DN 129:67773

TI Preparation of benzamide derivatives having a vasopressin antagonistic activity



IN Setoi, Hiroyuki; Ohkawa, Takehiko; Zenkoh, Tatsuya; Sawada, Hitoshi; Sawada, Yuki; Oku, Teruo

PA Fujisawa Pharmaceutical Co., Ltd., Japan

SO PCT Int. Appl., 332 pp.

CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9824771	A1	19980611	WO 1997-JP4192	19971118
	W: AU, CA, CN, HU, IL, JP, KR, MX, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9749672	A	19980629	AU 1997-49672	19971118
	EP 946519	A1	19991006	EP 1997-912493	19971118
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	JP 2001505193	T	20010417	JP 1998-521225	19971118
	US 6207693	B1	20010327	US 1999-308662	19990602
	US 6316482	B1	20011113	US 2000-614132	20000711
PRAI	AU 1996-3953	A	19961202		
	WO 1997-JP4192	W	19971118		
	US 1999-308662	A3	19990602		
OS	MARPAT 129:67773				
GI					




AB The title comps. [I; R1 = (un)substituted aryl, cyclo(lower)alkyl, heterocyclyl; R2 = H, lower alkyl, etc.; R3 = H, halo, OH, etc.; A = a single bond, O, NH; E = lower alkylene, lower alkenylene, etc.; X = CH:CH, CH:N, S; Y = (un)substituted aryl, condensed heterocyclyl, etc.] and their pharmaceutically acceptable salts, useful in treatment and/or prevention of hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome, hepatocirrhosis, hyponatremia, hypokalemia, diabetic, circulation disorder, cerebrovascular disease, Meniere's disease or motion sickness, were prepared Thus, the title compound II showed IC50 of 1.5 nM against vasopressin 1 receptor binding.

IT 208770-26-7P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzamide derivs. having a vasopressin antagonistic activity)
 RN 208770-26-7 CAPLUS
 CN 1,4-Benzenedicarboxamide, N4-[(2-amino-4-methylphenyl)methyl]-2-methoxy-N4-methyl-N1-(2-methyl-1H-benzimidazol-4-yl)-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



● 2 HCl

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT